menu
    • menu

    Company profile for Helocyte

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”).Developer of immunotherapies designed for the treatment and prevention of cancer and infectious disease. The company develops PepVax and Triplex vaccines for the t...
    Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”).Developer of immunotherapies designed for the treatment and prevention of cancer and infectious disease. The company develops PepVax and Triplex vaccines for the treatment of cancer and infectious diseases like cytomegalovirus or CMV, enabling customers to lower the risk of cancer.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HelocyteUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Gansevoort Street 9th Floor New York, NY 10014
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://helocyte.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Global ChemShow

    Not Confirmed

    envelop Contact Supplier

    Global ChemShow

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fortress Subsidiary Helocyte Announces Option Agreement with City of Hope
    Fortress Subsidiary Helocyte Announces Option Agreement with City of Hope

    16 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/16/2760729/28889/en/Fortress-Biotech-Subsidiary-Helocyte-Announces-Option-Agreement-with-City-of-Hope-for-Exclusive-Worldwide-Rights-to-use-a-Novel-Bispecific-CMV-HIV-CAR-T-Cell-Therapy-optionally-in-.html

    GLOBENEWSWIRE
    16 Oct 2023
    Share Share
    Helocyte Announces $3.22 M Grant from the NCI for Triplex Ph2 Trial Program
    Helocyte Announces $3.22 M Grant from the NCI for Triplex Ph2 Trial Program

    15 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/15/2688861/28889/en/Helocyte-Announces-3-22-Million-Grant-from-the-National-Cancer-Institute-for-Triplex-Phase-2-Clinical-Trial-Program.html

    GLOBENEWSWIRE
    15 Jun 2023
    Share Share
    Helocyte Announces Data from Stem Cell Transplant Donor Vaccination Trial
    Helocyte Announces Data from Stem Cell Transplant Donor Vaccination Trial

    16 Feb 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/02/16/2609775/28889/en/Helocyte-Inc-Announces-Positive-Data-from-Stem-Cell-Transplant-Donor-Vaccination-Trial-to-be-Presented-at-the-2023-Tandem-Meetings-Transplantation-Cellular-Therapy-Meetings-of-ASTC.html

    GLOBENEWSWIRE
    16 Feb 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search